LFMD Form 4: 50,000 Shares Vest for Chief Marketing Officer

Rhea-AI Filing Summary

LifeMD insider Jessica Friedeman acquired 50,000 shares of common stock upon vesting of performance stock on 08/22/2025. The Form 4 shows the transaction was reported on 08/26/2025 and lists Friedeman's role as Officer — Chief Marketing Officer. The filing reports 220,000 shares of common stock beneficially owned by the reporting person after the transaction. The acquisition is recorded as non‑derivative, with a reported price of $0 reflecting the vesting of previously granted performance stock.

Positive

• 50,000 common shares were acquired through the vesting of performance stock on 08/22/2025
• Reporting person’s beneficial ownership increased to 220,000 shares post‑transaction
• Filing clearly identifies reporting person’s role as Chief Marketing Officer and includes signed disclosure dated 08/26/2025

Negative

• None.

Insights

Financial Analyst

TL;DR: An officer received 50,000 common shares via vesting, raising beneficial ownership to 220,000 shares; this is a routine insider vesting event.

The Form 4 documents a non‑derivative acquisition of 50,000 shares by Jessica Friedeman on 08/22/2025 recorded as vested performance stock at a $0 price, with 220,000 shares held after the transaction. For investors, this is a disclosure of insider holdings and a standard reporting of compensation vesting rather than an open‑market purchase or sale. No additional financial terms, cash consideration, or derivative exercises are reported.

Corporate Governance Expert

TL;DR: The filing is a standard Section 16 disclosure showing grant vesting; it notifies stakeholders of an officer's increased beneficial ownership.

The document identifies the reporting person as Chief Marketing Officer and reports the vesting of performance stock on 08/22/2025 resulting in a 50,000 share acquisition and a post‑transaction ownership of 220,000 shares. The signature block and explanatory note explicitly state the acquisition represents vested performance stock. There are no indications of changes to officer status or employment terms within this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FRIEDEMAN JESSICA

(Last) (First) (Middle)

C/O LIFEMD

236 FIFTH AVENUE, SUITE 400

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		A		50,000	A	$0(1)	220,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents grant of performance stock which vested on August 22, 2025

	/s/ Jessica Friedeman	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Jessica Friedeman report on Form 4 for LifeMD (LFMD)?

The Form 4 reports the vesting of performance stock resulting in the acquisition of 50,000 common shares on 08/22/2025.

How many shares does the reporting person beneficially own after the transaction?

The filing states the reporting person beneficially owns 220,000 common shares following the reported transaction.

What was the reported price for the shares acquired by Jessica Friedeman?

The reported price is shown as $0, reflecting that the shares were from vested performance stock.

What is Jessica Friedeman’s relationship to LifeMD in the filing?

The Form 4 identifies Jessica Friedeman as an Officer with the title Chief Marketing Officer.

When was the Form 4 signed and filed?

The signature block is dated and signed on 08/26/2025.